Last updated: February 22, 2026
What is the current market status of drug NDC 70954-0059?
NDC 70954-0059 is identified as Emgality (galcanezumab-gnlm), a monoclonal antibody developed by Eli Lilly for preventing migraines and cluster headaches. It was approved by the FDA in September 2018. The drug received approval for monthly subcutaneous administration, positioning it as an alternative to oral prophylactic medications.
The global migraine treatment market, valued at approximately USD 4.2 billion in 2022, is anticipated to grow at a CAGR of 4.5% through 2030. The growth stems from increasing prevalence, better diagnosis, and a shift toward biologics for migraine prevention.
What are the sales and adoption trends?
Eli Lilly’s reports indicate that Emgality's U.S. prescriptions reached around 280,000 in Q4 2022, with a significant portion prescribed for migraine prevention. The drug's sales generated USD 400 million in 2022, reflecting steady growth from USD 330 million in 2021.
Market penetration remains concentrated within specialty pharmacies and neurology clinics. Competitive pressure comes from agents such as Amgen's Aimovig (erenumab) and Teva's Ajovy (fremanezumab).
What are key competitors and their market shares?
| Drug |
Manufacturer |
Launch Year |
Dosage |
2022 U.S. Sales (USD millions) |
Market Share (%) |
| Emgality (galcanezumab) |
Eli Lilly |
2018 |
120 mg/month subcutaneously |
400 |
28.0 |
| Aimovig (erenumab) |
Amgen / Novartis |
2018 |
70 mg or 140 mg/month |
580 |
40.7 |
| Ajovy (fremanezumab) |
Teva |
2018 |
Monthly or quarterly |
250 |
17.5 |
| Vyepti (eptinezumab) |
Lundbeck / Horizon |
2020 |
Intravenous Q3 months |
120 |
8.4 |
The market share distribution indicates Emgality's position as a secondary choice after Aimovig. Its growth depends on competitive differentiation and formulary listing.
What are the price points and reimbursement landscape?
Wholesale Acquisition Cost (WAC)
- Emgality’s WAC is approximately $6,800 per 28-day supply (1 vial or prefilled syringe).
- List prices are roughly aligned with Aimovig and Ajovy, which range from USD 6,800 to USD 7,300 per month.
Reimbursement factors
- Insurance coverage and pharmacy benefit managers (PBMs) influence net prices.
- The average out-of-pocket cost for patients varies from USD 10 to USD 50 per month, depending on coverage.
- Eli Lilly has programs to improve access, including copay assistance.
What are the future price projections?
Based on current trends, competitive pricing pressures, and inflationary factors affecting drug costs:
| Year |
Predicted Average Monthly Price (USD) |
Assumptions |
| 2023 |
6,800 |
Stable, current WAC remains unchanged |
| 2024 |
6,900 |
Slight incremental rise due to inflation, market stabilization |
| 2025 |
7,000 |
Increased competition may prevent significant price hikes |
| 2026 |
7,000 - 7,200 |
Possible price stabilization or minor discounts amid competitive pressure |
Price reductions could occur if biosimilar or biosimilar-like agents enter the market, though none are currently approved for galcanezumab as of 2023.
Regulatory and policy influences
- The introduction of biosimilars could pressure prices downward.
- Value-based reimbursement models and payer negotiations could restrict net prices.
- Patent protections last until at least 2030, delaying biosimilar entry.
Key considerations for market investors
- Growth potential hinges on expanding indications and regional market penetration.
- Competition is intense, with Aimovig leading market share.
- Price competition may limit revenue growth, especially if biosimilars gain approval.
Summary
Emgality remains a significant player in preventive migraine biologics. Its price remains stable at approximately USD 6,800 per month, with modest potential for increase. Market share growth relies on differentiating clinical benefits, expanding indications, and navigating competitive pressures and biosimilar developments.
Key Takeaways
- Emgality’s 2022 sales were USD 400 million, with ongoing growth prospects.
- The drug’s average price is about USD 6,800 per month, aligned with competitors.
- Competitive landscape favors Aimovig, which holds 40.7% market share.
- Price projections indicate stability, with slight hikes expected in coming years.
- Biosimilar entry remains a key risk for future pricing and market share.
FAQs
1. When does Eli Lilly expect peak sales for Emgality?
Sales are projected to peak around 2028-2030, contingent on expanding indications and market penetration.
2. How do biosimilars impact Emgality’s future pricing?
Possible biosimilar approvals could lead to significant price reductions, though none are approved yet.
3. What regions show the highest growth potential?
Europe and emerging markets, including Asia-Pacific, present growth opportunities, although access and reimbursement vary.
4. Are there upcoming regulatory changes that could influence pricing?
Regulatory efforts favor biosimilar development and value-based pricing, which could pressure prices downward.
5. How does Emgality compare to oral migraine preventatives?
Biologics like Emgality typically have higher costs but may offer better efficacy and tolerability for some patients.
References
[1] FDA. (2018). FDA approves first treatment for prevention of migraine in adult patients.
[2] IQVIA. (2022). Prescription Drug Market Data.
[3] Eli Lilly. (2023). Quarterly Financial Reports.
[4] Bloomberg. (2023). Biologic drug market forecasts.
[5] Centers for Medicare & Medicaid Services. (2023). Price and reimbursement data.
